OncohematologyOncohematologyОнкогематология1818-83462413-4023Publishing House ABV Press70610.17650/1818-8346-2009-0-1-21-28HEMATOLOGIC MALIGNANCIES: TREATMENT, SUPPORTIVE CAREГЕМОБЛАСТОЗЫ: ЛЕЧЕНИЕ, СОПРОВОДИТЕЛЬНАЯ ТЕРАПИЯBortezomib neurotoxicity treatment of multiple myeloma: single center experience and literature reviewНейротоксичность бортезомиба в лечении множественной миеломы: опыт одного центра и обзор литературыStepanovaN. V.СтепановаН. В.
Russian Federation
MachulaiteneE. R.МачюлайтенеЕ. Р.
Russian Federation
SalogubG. N.СалогубГ. Н.
Russian Federation
MelnikovaE. V.МельниковаЕ. В.
Russian Federation
St.-Petersburg State Pavlov Medical UniversityСанкт-Петербургский государственный медицинский университет им. акад. И. П. Павлова240220091212824112022241120222009https://oncohematology.abvpress.ru/ongm/article/view/706

Peripheral neuropathy is one of the most common complications of Bortezomib treatment. In this article you can find a brief literature review and single center experience: we estimated the prevalence of neuropathy development and it’s characteristics in a group of 33 patients. Peripheral neuropathy was found in 16 (48.5%) patients. In this group initial manifestations of neurotoxicity (grade I and II) were found in 8 (50%) patients. Advanced neuropathy (grade III and IV) was found in 6 (37.5%) and 2 (12.5%) patients respectively. In the majority of patients neuropathy was reversible if Bortezomibe dose was modified and symptomatic treatment was administered at the proper time.

Периферическая нейропатия (ПН) — одно из самых частых осложнений терапии бортезомибом. В статье приведен краткий обзор литературы, а также оценена частота возникновения нейропатии, ее характеристика в группе, состоящей из 33 больных. ПН была выявлена у 16 (48,5%) пациентов. В этой группе начальные проявления нейротоксичности (I и II степени) отмечены у 8 (50%) больных, тогда как проявления тяжелой нейропатии III и IV степени — у 6 (37,5%) и 2 (12,5%) больных соответственно. Нейропатия у большинства пациентов была обратима при своевременной модификации дозы препарата и назначении симптоматической терапии.

bortezomibmultiple myelomaperipheral neuropathyбортезомибмножественная миеломапериферическая нейропатия1. Richardson P.G., Barlogie B., Berenson J. et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003;348(26):2609—17.Richardson P.G., Barlogie B., Berenson J. et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003;348(26):2609—17.2. Jagannath S., Barlogie B., Berenson J. et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 2004;127(2):165—72.Jagannath S., Barlogie B., Berenson J. et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 2004;127(2):165—72.3. Durie B.G.M., Kyle R., Belch A. et al. Myeloma management guidelines. Hematol J 2003;4:379—98.Durie B.G.M., Kyle R., Belch A. et al. Myeloma management guidelines. Hematol J 2003;4:379—98.4. Cancer therapy evaluation program. Common terminology criteria for adverse events, version 3. http://ctep.cancer.govCancer therapy evaluation program. Common terminology criteria for adverse events, version 3. http://ctep.cancer.gov5. Boccadoro M., Marmont F., Tribalto M. et al. Multiple myeloma: VMCP/VBAP alternating combination chemotherapy is not superior to melphalan and prednisone even in high-risk patients. J Clin Oncol 1991;9:444—8.Boccadoro M., Marmont F., Tribalto M. et al. Multiple myeloma: VMCP/VBAP alternating combination chemotherapy is not superior to melphalan and prednisone even in high-risk patients. J Clin Oncol 1991;9:444—8.6. Borrello I., Ferguson A., Huff C.A. et al. Bortezomib and thalidomide treatment of newly diagnosed patients with multiple myeloma. Efficacy and neurotoxicity. ASH Annual Meeting Abstracts. Blood 2006;108:abstr 3528.Borrello I., Ferguson A., Huff C.A. et al. Bortezomib and thalidomide treatment of newly diagnosed patients with multiple myeloma. Efficacy and neurotoxicity. ASH Annual Meeting Abstracts. Blood 2006;108:abstr 3528.7. Chaudhry V., Cornblath D.R., Corse A. et al. Thalidomide-induced neuropathy. Neurology 2002;59(12):1872—5.Chaudhry V., Cornblath D.R., Corse A. et al. Thalidomide-induced neuropathy. Neurology 2002;59(12):1872—5.8. Rooper A.H., Gorson K.C. Neuropaties associated with paraproteinemia. N Engl J Med 1998;338 (22):1601—9.Rooper A.H., Gorson K.C. Neuropaties associated with paraproteinemia. N Engl J Med 1998;338 (22):1601—9.9. Badros A., Goloubeva O., Dalal J.S. et al. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature. Cancer 2007;110(5):1042—9.Badros A., Goloubeva O., Dalal J.S. et al. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature. Cancer 2007;110(5):1042—9.10. Cavaletti G., Nobile-Orazio E. Bortezomib-induced peripheral neurotoxicity: still far from a painless gain. Haematologica 2007;92(10):1308—10.Cavaletti G., Nobile-Orazio E. Bortezomib-induced peripheral neurotoxicity: still far from a painless gain. Haematologica 2007;92(10):1308—10.11. Gupta S., Pagliuca A., Devereux S. et al. Life-threatening motor neurotoxicity in association with bortezomib. Haematologica 2006;91(7):1001.Gupta S., Pagliuca A., Devereux S. et al. Life-threatening motor neurotoxicity in association with bortezomib. Haematologica 2006;91(7):1001.12. Гринберг Д.А., Аминофф М.Д., Саймо Р.П. Клиническая неврология. М.: Медэкспресс-информ, 2004. с. 282—314.Гринберг Д.А., Аминофф М.Д., Саймо Р.П. Клиническая неврология. М.: Медэкспресс-информ, 2004. с. 282—314.13. Jagannath S., Richardson P.G., Briemberg H. et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 2006;24(19):3113—20.Jagannath S., Richardson P.G., Briemberg H. et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 2006;24(19):3113—20.14. Caravita T., Petrucci M.T., Spagnoli A. et al. Neuropathy in multiple myeloma patients treated with bortezomib: a multicenter experience. ASH Annual Meeting Abstracts. Blood 2007;110:abstr 4823.Caravita T., Petrucci M.T., Spagnoli A. et al. Neuropathy in multiple myeloma patients treated with bortezomib: a multicenter experience. ASH Annual Meeting Abstracts. Blood 2007;110:abstr 4823.15. Бессмельцев С.С., Карягина Е.В., Стельмашенко Л.В. и др. Частота, характеристика и методы лечения периферической нейропатии у больных множественной миеломой, получавших бортезомиб (велкейд). Онкогематология 2008;3:52—62.Бессмельцев С.С., Карягина Е.В., Стельмашенко Л.В. и др. Частота, характеристика и методы лечения периферической нейропатии у больных множественной миеломой, получавших бортезомиб (велкейд). Онкогематология 2008;3:52—62.16. Levine S., Saltzman A. Pyridoxine (vitamin B6) toxicity: enhancement by uremia in rats. Food Chem Toxicol 2002;40(10):1449—51.Levine S., Saltzman A. Pyridoxine (vitamin B6) toxicity: enhancement by uremia in rats. Food Chem Toxicol 2002;40(10):1449—51.17. Teoh G., Tan D., Hwang W. et al. Use of immunoglobulin infusions in the management of bortezomib-induced peripheral neuropathy in multiple myeloma. ASH Annual Meeting Abstracts. Blood 2006;108:abstr 5097.Teoh G., Tan D., Hwang W. et al. Use of immunoglobulin infusions in the management of bortezomib-induced peripheral neuropathy in multiple myeloma. ASH Annual Meeting Abstracts. Blood 2006;108:abstr 5097.18. Catley L., Anderson K.C. Velcade and vitamin C: too much of a good thing? Clin Cancer Res 2006;12(1):3—4.Catley L., Anderson K.C. Velcade and vitamin C: too much of a good thing? Clin Cancer Res 2006;12(1):3—4.